ALK and lung carcinoma: Both Dr. Pasi Jαnne's team and Dr. Jeffrey Settleman's teams were able to screen lung cancer cell lines, most arising from patients treated in the intramural program and were able to identify two different cell lines, NCI‐H2228 and 3122, with ALK rearrangements which were exquisitely sensitive to the drug, crizotinib, which could target ALK.46, 47 Crizotinib was already in clinical trials starting in 2006 so an ALK‐rearranged cohort was added to the drug development protocol.